JPMorgan assumed coverage of InnovAge (INNV) with an Underweight rating and $5 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. The analyst believes InnovAge is facing challenges balancing growth while navigating the regulatory backdrop.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INNV: